ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1520

RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year

Susan M. Goodman1, Susan J. Bartlett2, Ryan Cummings3, Kathleen Andersen3, Edward F. DiCarlo4, Mark P. Figgie5, Laura T. Donlin6, Dana E. Orange7 and Vivian P. Bykerk8, 1Medicine, Hospital for Special Surgery, New York, NY, 2Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 3Hospital for Special Surgery, New York, NY, 4Laboratory Medicine, Hospital for Special Surgery, New York, NY, 5Orthopaedics, Hospital for Special Surgery, New York, NY, 6Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Divison of Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Arthroplasty, outcomes and rheumatoid arthritis (RA), Perioperative management

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Post-op flares are frequent for RA patients after total hip (THA) and total knee arthroplasty (TKA), when medications are discontinued to mitigate infection risk. The association of flares and patient-reported outcomes (PROs) at 1 year after THA and TKA is unknown. We aimed to describe the relationship of post-op flares with 1 year THA/TKA outcomes.

Methods : Post-op flares were identified in patients with RA undergoing TKA/THA by self-report. Patients completed a questionnaire comprised of a subset of questions from the RA Flare Questionnaire, administered weekly for 6 weeks after arthroplasty. Flare was defined by concordance between patient report (“Are you in a flare? Yes/No”), plus MD assessment of patient-reported survey data including patient reported swollen and tender joints and Rapid III. Pain and function scores (HOOS/KOOS) and disease characteristics were collected at baseline before surgery and after one year.  Baseline characteristics and HOOS/KOOS scores were compared using t-tests and chi-square.

Results: One-year outcome scores were available for 20 THA and 14 TKA patients, predominantly women with established RA (Table 1). Baseline DAS-28 and CDAI were higher in TKA flarers, but not THA flarers. 20 (59%) were using biologic medications that were stopped for surgery, and 21 (61%) were flaring before or within six weeks of surgery. MTX use was similar in all groups. Despite this, flarers and non-flarers both had excellent pain and function outcomes at 1 year. There was no statistically or clinically significant difference between flarers and non-flarers, despite poorer pre-operative KOOS scores and higher disease activity for TKA flarers.

Conclusion: Although post-op flares were frequent in RA patients undergoing THA/TKA, pain and function outcomes were similar at 1 year in those who reported flare or not. While these preliminary data are reassuring that perioperative flares do not appear to affect long term functional outcomes, further validation in a larger sample of patients is needed, as well as more study in different settings to increase confidence in these findings. This study was supported by the Clinical Translational Science Center (CTSC) (UL1-TR000457-06)

   


Disclosure: S. M. Goodman, None; S. J. Bartlett, None; R. Cummings, None; K. Andersen, None; E. F. DiCarlo, None; M. P. Figgie, Lima Corporate, 7,Knee Society, 6; L. T. Donlin, None; D. E. Orange, None; V. P. Bykerk, NIH, 2.

To cite this abstract in AMA style:

Goodman SM, Bartlett SJ, Cummings R, Andersen K, DiCarlo EF, Figgie MP, Donlin LT, Orange DE, Bykerk VP. RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/ra-flare-after-total-hip-and-total-knee-arthroplasty-preliminary-outcomes-at-1-year/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ra-flare-after-total-hip-and-total-knee-arthroplasty-preliminary-outcomes-at-1-year/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology